You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. NIH/NIA 006: The Development of Mechanism-based Adult Stem Cell Treatments to Combat Aging Pathologies

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast- Track proposals will be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 1 to 2 Budget (total costs, per award): Phase I: $350,000 for 12 months; Phase II: $2,000,000 for 2 years It is strongly suggested that proposals adhere to the above budget amounts and project periods. Proposals with budgets exceeding the above amounts and project periods may no ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. NIH/NIAID 101: Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track Proposals will be accepted. Direct-to-Phase II will not be accepted. Number of anticipated awards: 2-4 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $2,000,000 for up to 3 years. Background Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broa ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. NIH/NIAID 102: Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast Track Proposals will be accepted. Direct to Phase II will not be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $2,000,000 for up to 3 years. Background The development of novel HIV candidate vaccines generally requires preclinical testing in animal models before proceeding to Phase I clinical trials. Multiple efforts have focus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. NIH/NIAID 103: Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast Track Proposals will be accepted. Direct-to-Phase II will not be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $ 300,000 for up to 1 year; Phase II: $ 2 million for up to 3 years. Background HIV/AIDS continues to be a major health problem throughout the world, with the greatest impact on vulnerable and underserved populations. A safe and effective HIV vaccine has ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. NIH/NIAID 104: Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000/year for up to 2 years; Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years. Background The goal of this program is to support the screening for new vaccine adjuvant candidates against infectious dise ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. NIH/NIAID 105: Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Page 109 Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000/year for up to 2 years; Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years. Background The goal of this program is to support the preclinical development of novel vaccine adjuvants for use ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. NIH/NIAID 106: Production of Adjuvants Mimics

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Number of anticipated awards: 3-5 Budget (total costs): Phase I: $300,000/year for up to 2 years; Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years. Page 111 Background Many experimental and licensed vaccines depend on adjuvants to exert their protective effect. While sev ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. NIH/NIAID 107 : Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Number of anticipated awards: 3-6 Budget (total costs): Phase I: $300,000/year for up to 2 years; Phase II: $1,500,000 with appropriate justification by the applicant for up to 3 years. Page 112 Background This program addresses the limited availability of reagents (e.g., antibodies, proteins, ligands) for the id ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. NIH/NIAID 108: Development of Rapid POC Diagnostics for Treponema pallidum

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct to Phase II proposals will not be accepted. Number of anticipated awards: 1-2 Budget (total costs): Phase I: up to $300,000 for up to 1 year; Phase II: up to $1,500,000 for up to 3 years. Background Cases of syphilis, caused by the pathogen T. pallidum, are increasing in the US and globally. In 2018, the total number of syphilis cases (all stages) in t ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. NIH/NIAID 109: Development of monoclonal antibody-mediated interventions to combat malaria

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will not be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: up to $300,000 for up to 1 year; Phase II: up to $1,500,000 for up to 3 years. Background According to the World Malaria Report 2020, progress towards malaria control and elimination appears to be slowing in recent years. Although a moderately e ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government